Previous Article | Next Article ![]()
Infection and Immunity, December 2000, p. 6643-6649, Vol. 68, No. 12
Department of Pathobiology and Center of
Excellence for Vaccine Research, The University of Connecticut,
Storrs, Connecticut 06269-3089
Received 2 May 2000/Returned for modification 29 June 2000/Accepted 28 August 2000
Comparison of the phenotypic expression of Mycoplasma
gallisepticum strain R low (passage 15) to that of strain R high
(passage 164) revealed that three proteins, i.e., the cytadhesin
molecule GapA, a 116-kDa protein (p116), and a 45-kDa protein (p45),
are missing in strain R high. Sequence analysis confirmed that the insertion of an adenine 105 bp downstream of the gapA
translational start codon resulted in premature termination of
translation in R high. A second adenine insertion had also occurred at
position 907. Restoration of expression of wild-type gapA
in R high (clone designated GT5) allowed us to evaluate the extent to
which the diminished cytadherence capacity could be attributed to GapA
alone. The results indicated that GT5 attached to the same limited
extent as the parental R high, from which it was derived. The
cytadherence capability of the parental R high was not restored solely
by gapA complementation alone, indicating that either p116
or p45 or both may play a role in the overall cytadherence process. The
gene encoding p116 was found to be immediately downstream of
gapA in the same operon and was designated
crmA. This gene exhibited striking homology to genes
encoding molecules with cytadhesin-related functions in both
Mycoplasma pneumoniae and Mycoplasma
genitalium. Transcriptional analysis revealed that
crmA is not transcribed in R high. We are currently
constructing a shuttle vector containing both the wild-type gapA and crmA for transformation into R high to
assess the role of CrmA in the cytadherence process.
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Analysis of Cytadherence-Deficient, GapA-Negative
Mycoplasma gallisepticum Strain R


*
Corresponding author. Mailing address: Department of
Pathobiology and The Center of Excellence for Vaccine Research, U-89, 61 N. Eagleville Rd., University of Connecticut, Storrs, CT 06269-3089. Phone: (860) 486-0835. Fax: (860) 486-2794. E-mail:
geary{at}uconnvm.uconn.edu.
Present address: Vion Pharmaceuticals, New Haven, CT 06511.
Present address: Department of Therapeutic Radiology, Yale
University School of Medicine, New Haven, CT 06520-8040.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»